Apatinib is a new potent oral inhibitor of VEGFR-2, c-kit, and c-src that has demonstrated activity in Chinese patients with hepatocellular carcinoma, gastric cancer, and also ES-SCLC (43–46). Here, KDR is linked to small cell lung carcinoma.